Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.
Karacin C, Sunar V, Urakci Z, Yilmaz A, Ayhan M, Ersoy M, Guven DC, Erturk I, Durmus Y, Karacin P, Boran N, Ustun YE, Meydan M, Dogan M, Oksuzoğlu B, Ates O, Karaca M, Uncu D, Ergun Y, Arik Z. Karacin C, et al. Among authors: guven dc. Future Oncol. 2024 Feb;20(4):207-214. doi: 10.2217/fon-2023-0763. Epub 2024 Feb 8. Future Oncol. 2024. PMID: 38328890
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, Acar O, Aksoy S, Baytemur NK, Sahin E, Cabuk D, Basaran G, Paydas S, Yaren A, Guven DC, Erdogan AP, Demirci U, Yasar A, Bayoglu İV, Hizal M, Gulbagci B, Paksoy N, Davarci SE, Yilmaz F, Dogan O, Orhan SO, Kayikcioglu E, Aytac A, Keskinkilic M, Mocan EE, Unal OU, Aydin E, Yucel H, Isik D, Eren O, Uluc BO, Ozcelik M, Hacibekiroglu I, Aydiner A, Demir H, Oksuzoglu B, Cilbir E, Cubukcu E, Cetin B, Oktay E, Erol C, Okutur SK, Yildirim N, Alkan A, Selcukbiricik F, Aksoy A, Karakas Y, Ozkanli G, Duman BB, Aydin D, Dulgar O, Er MM, Teker F, Yavuzsen T, Aykan MB, Inal A, Iriagac Y, Kalkan NO, Keser M, Sakalar T, Menekse S, Kut E, Bilgin B, Karaoglanoglu M, Sunar V, Ozdemir O, Turhal NS, Karadurmus N, Yalcin B, Sendur MAN. Kahraman S, et al. Among authors: guven dc. Future Oncol. 2023 Mar;19(10):727-736. doi: 10.2217/fon-2022-1287. Epub 2023 May 3. Future Oncol. 2023. PMID: 37133230
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey.
Akyildiz A, Guven DC, Ozluk AA, Ismayilov R, Mutlu E, Unal OU, Yildiz I, Iriagac Y, Turhal S, Akbas S, Bayram E, Telli TA, Turkoz FP, Ozcelik M, Erciyestepe M, Selvi O, Gulbagci B, Erturk I, Isleyen ZS, Kahraman S, Akdag MO, Hamitoglu B, Unek IT, Unal C, Hacibekiroglu İ, Arslan C, Azizy A, Helvaci K, Demirci U, Dizdar O, Basaran M, Goker E, Sendur MA, Yalcin S. Akyildiz A, et al. Among authors: guven dc. Medicine (Baltimore). 2023 Nov 10;102(45):e35950. doi: 10.1097/MD.0000000000035950. Medicine (Baltimore). 2023. PMID: 37960746 Free PMC article.
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.
Köstek O, Demirel A, Hacıoğlu MB, Tastekin D, Karabulut S, Gündogdu A, Sever N, Ayhan M, Çelebi A, Majidova N, Yaşar A, Ağyol Y, Erel P, Kocaaslan E, Güren AK, Arıkan R, Isık S, Ercelep O, Goksu SS, Alandag C, Bilgetekin İ, Caner B, Sahin AB, Gulmez A, Akagunduz B, Kose F, Kaplan MA, Dogan E, Sakalar T, Guven DC, Gurbuz M, Ergun Y, Karaagac M, Turker S, Ozkul O, Yıldız B, Sahin S, Demiray AG, Sari M, Erdogan B, Hacıbekiroglu İ, Çakmak Öksüzoğlu ÖB, Kilickap S, Bilici A, Bayoglu İV, Topaloglu S, Cicin İ. Köstek O, et al. Among authors: guven dc. J Chemother. 2024 Nov;36(7):613-621. doi: 10.1080/1120009X.2024.2305066. Epub 2024 Jan 23. J Chemother. 2024. PMID: 38263804
Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab.
Yildirim HC, Anik H, Ozdemir DA, Ismayilov R, Akyildiz A, Cayiroz K, Ceyhan F, Kavruk O, Guven DC, Ates O, Usubutun A, Arik Z. Yildirim HC, et al. Among authors: guven dc. Biomol Biomed. 2024 Mar 5;24(4):998-1003. doi: 10.17305/bb.2024.10255. Biomol Biomed. 2024. PMID: 38447002 Free PMC article.
The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer.
Yildirim HC, Buyukkor M, Kavgaci G, Celik BŞ, Yucel KB, Dursun B, Chalabiyev E, Yilmaz F, Yildirim SS, Kus F, Tay F, Gecgel A, Koksal B, Guven DC, Yazici O, Urun Y, Ozet A, Gokmen E, Oksuzoglu B, Aksoy S. Yildirim HC, et al. Among authors: guven dc. Medicine (Baltimore). 2024 Jul 26;103(30):e38828. doi: 10.1097/MD.0000000000038828. Medicine (Baltimore). 2024. PMID: 39058877 Free PMC article.
154 results